The British journal of surgery
-
Multicenter Study
Multicentre study of neoadjuvant chemotherapy for stage I and II oesophageal cancer.
The benefit of neoadjuvant chemotherapy (NCT) for early-stage oesophageal cancer is unknown. The aim of this study was to assess whether NCT improves the outcome of patients with stage I or II disease. ⋯ NCT was associated with better overall and disease-free survival in patients with stage I or II oesophageal cancer, without increasing postoperative morbidity.